Gi Insights

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Arlene Wright, DNP, APRN, FNP-BC, FNAP Thanks to recent research and advancements, our understanding and treatment of gastroesophageal reflux disease (GERD) has greatly evolved over the years. So what do we now know about diagnosing and treating this common GI disorder? Find out with Dr. Peter Buch and Dr. Arlene Wright, President of the Florida Nurse Practitioner Network and Executive Vice President of the Nurse Practitioners of Lee County, Florida.

Host: Neilanjan Nandi, MD Guest: Freddy Caldera, DO Many IBD patients have received their COVID-19 vaccine, but many others still have reservations due to the abundance of myths and misconceptions surrounding the COVID-19 vaccines. That’s why Dr. Neil Nandi welcomes Dr. Freddy Caldera to discuss these common fears and challenges as well as some of the very best answers to address the concerns of our immunosuppressed IBD patients.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Rajeev Attam, MD Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterologist Dr. Rajeev Attam.

Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD With more data emerging on COVID-19 vaccines every day, what do our patients with inflammatory bowel disease need to know about the vaccine currently available? Dr. Neil Nandi will be discussing these updates and how we can keep our patients safe with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine.

Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD How has the COVID-19 pandemic impacted patients with IBD? Dr. Neil Nandi is here to answer our COVID-19 questions for our IBD patients with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Colin T. Swales, MD Should sobriety and drug abstinence be required for hepatitis C therapy? Dr. Peter Buch dives into this dilemma with Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital, as he walks us through both sides of this controversial issue.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Colin T. Swales, MD From cirrhosis to liver cancer, there are many dangers associated with non-alcoholic fatty liver disease. So what are some best practices for managing this condition? Dr. Peter Buch sits down with Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital, to discuss the management of non-alcoholic fatty liver disease.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Colin T. Swales, MD How can we help the two to four million Americans who are living with hepatitis C? Joining Dr. Peter Buch to answer this question and share treatment strategies for various case scenarios is hepatologist Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Adam Olsen, MS, PA-C Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD Guest: Johannah Ruddy, MEd Patients suffering from disorders of the gut-brain interaction are often subjected to stigma. But what can we do to help challenge these stigmas? Here today is Dr. Peter Buch who will be joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to talk about the impact of stigma in DGBI.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD Guest: Johannah Ruddy, MEd Strong communication is a critical component in improving health outcomes for patients with IBS. What do we need to know to help our patients feel heard and valued? Dr. Peter Buch is joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to discuss how to effectively communicate with our patients.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Andres Nieto, MD The COVID-19 pandemic has demonstrated the effectiveness of telemedicine, but will this approach still be utilized after the pandemic ends? Dr. Peter Buch is joined by Dr. Andres Nieto, Assistant Professor at Frank H. Netter MD School of Medicine, to discuss the role of telemedicine and its future

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Scott Gabbard, MD Dyspepsia affects a large number of Americans. But what exactly is dyspepsia? And how can we distinguish dyspepsia from other diseases? Joining Dr. Peter Buch to answer those and other questions is Dr. Scott Gabbard, who’s the section head of the Neurogastroenterology and Motility Center at the Cleveland Clinic.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: John Allen, MD The world of healthcare continues to drastically change over the years. But what do you need to know about the variety of employment models available for gastroenterologists today? Dr. Peter Buch is joined by Dr. John Allen, Clinical Professor of Medicine at the University of Michigan School of Medicine, to discuss recent changes in practice models.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas K. Rex, MD Millions of colonoscopies are performed each year in the United States, but which indicators should we be using to measure the quality of these procedures? Dr. Peter Buch is joined by Dr. Douglas Rex, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, to discuss the importance of these indicators.

Host: Neilanjan Nandi, MD Guest: Folasade P. May, MD, PhD, MPhil Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Nicole Hanley-Williams, MD The management of motility disorders like achalasia and gastroparesis can be very complex for both patients and clinicians alike. Fortunately, there have been several advancements in the evaluation and treatment of these disorders. Joining Dr. Peter Buch to walk us through what those developments are and how they can help improve our patients’ quality of life is Dr. Nicole Hanley-Williams, who specializes in motility and functional disorders at Beth Israel Lahey Health.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Philip Ginsburg, MD Tofacitinib is a common treatment option for patients with ulcerative colitis. But it’s not without its risks. Here to share what we need to consider before we start our patients on tofacitinib is Dr. Philip Ginsburg, Medical Director of Research and the Director of the Inflammatory Bowel Disease Center of Connecticut.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Philip Ginsburg, MD With so many treatment options currently available for moderate to severe Crohn’s disease and ulcerative colitis, how do you know which one will work best for your patients? Joining Dr. Peter Buch to help answer that and other questions is Dr. Philip Ginsburg, Medical Director of Research and the Director of the Inflammatory Bowel Disease Center of Connecticut.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Jeffrey Basile, MD Now that we have therapies like vedolizumab and ustekinumab, many are wondering if there’s still a role for anti-TNFs in the treatment of IBD. Here to share his perspective and how he uses the multitude of available treatment options to his advantage is Dr. Jeffrey Basile, a gastroenterologist from Charleston GI.